RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
开发用于胰腺导管腺癌的细胞疗法
英文原题：Developing cell-based therapies for pancreatic ductal adenocarcinoma.
查看英文原题
Developing cell-based therapies for pancreatic ductal adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
前列腺干细胞抗原（PSCA）在胰腺导管腺癌（PDAC）细胞表面高表达且具有优先表达的特点，这为肿瘤选择性细胞免疫治疗带来了希望。在本期 JCI 中，Dai 等人利用 PSCA 开发了一种用于 PDAC 的现成嵌合抗原受体（CAR）恒定自然杀伤 T（iNKT）细胞治疗方法。通过体外实验和体内模型，作者证明了 PSCA CAR_sIL15 iNKT 细胞对吉西他滨敏感和耐药的 PDAC 细胞均具有选择性和治疗疗效，且新鲜制备和冷冻的现成 PSCA CAR_sIL15 iNKT 细胞具有相当的抗肿瘤活性。这一进展为胰腺癌开辟了另一种潜在的治疗选择。
展开英文摘要原文
Prostate stem cell antigen (PSCA) is highly and preferentially expressed on the surface of pancreatic ductal adenocarcinoma (PDAC) cells, raising the promise of tumor-selective cell-based immunotherapies. In this issue of the JCI, Dai et al. harness PSCA for the development of an off-the-shelf chimeric antigen receptor (CAR) invariant natural killer T (iNKT) cell-based treatment for PDAC.
Through in vitro experiments and in vivo models, the authors demonstrate selectivity and therapeutic efficacy of PSCA CAR_sIL15 iNKT cells against both gemcitabine-sensitive and -resistant PDAC cells with comparable antitumor activity for freshly produced and frozen off-the-shelf PSCA CAR_sIL15 iNKT cells. This development opens another potential therapeutic option for pancreatic cancer.
论文信息
- 作者
- Fincham REA、Yeong JPS、Kocher HM
- 单位
- Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.United Kingdom
- 期刊
- The Journal of clinical investigation2025 Apr 15
- 原文标识
- PubMed 40231460 · DOI 10.1172/JCI189513
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →